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ABSTRACT 
Introduction: Clinicians involved in pain management can finally include cannabis or cannabis-
related products in their therapeutic armamentarium as a growing number of countries have 
approved them for pain relief. Despite the several benefits attributed to analgesic, anti-
inflammatory and immunomodulatory properties of cannabinoids, there are still significant areas 
of uncertainty concerning their use in many fields of medicine.   
The biosynthesis and inactivation of cannabinoids are regulated by a complex signaling system of 
cannabinoid receptors, endocannabinoids (the endogenous ligands of cannabinoid receptors) and 
enzymes, with a variety of interactions with neuroendocrinological and immunological systems.  
Areas covered: A review of studies carried out during clinical development of cannabis and 
cannabis medical products in systemic rheumatic diseases was performed, highlighting the aspects 
that we believe to be relevant to clinical practice. 
Expert opinion: The growing public opinion, pushing towards the legalization of the use of 
cannabis in chronic pain and various rheumatological conditions, makes it necessary to have 
educational programs that modify the concerns and widespread preconceptions related to this 
topic in the medical community by increasing confidence. More extensive basic and clinical 
research on the mechanisms and clinical utility of cannabis and derivatives in various diseases and 
their long-term side effects is necessary. 
 
 
 
Ac
ce
pte
d M
an
us
cri
pt
 
 3
Information Classification: General 
Key words: Cannabis; endocannabinoid system; fibromyalgia; SLE; rheumatoid arthritis; 
cannabidiol;  tetrahydrocannabinol (THC) 
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Article Highlights 
• Cannabis and cannabis-based medicines are still little prescribed among healthcare 
providers; rather there are still conflicting positions adopted by professional associations. 
• The medical community (in particular general practitioners, but also pain specialists and 
rheumatologists), given the lack of large scale clinical trials, still doesn’t feel confident in 
using cannabinoid treatment, and therefore doesn’t recommend it. 
• There is an increasing public pressure to prescribe cannabis in a variety of chronic pain and 
rheumatologic conditions.  
• Educational programmes finalized to increase confidence in the medical community are 
necessary in order to modify widespread preconceptions and concerns related to this 
specific topic and allow a correct, rational and conscientious prescription from the medical 
community. 
• Basic and clinical research into the mechanisms and clinical usefulness of cannabis and 
cannabis-based medicines in various diseases are needed.  
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1.INTRODUCTION 
Clinicians involved in pain management can now include cannabis or cannabis-related products in 
their therapeutic armamentarium, as an increasing number of countries have approved its use. 
However, despite the known analgesic, anti-inflammatory and immunomodulatory effects, the 
uncertainty and controversy surrounding the scientific data make it difficult to establish the role 
and appropriate use of cannabis in the management of various diseases, particularly in the field of 
rheumatology [1-2].  
Pharmaceutical products usually go through a defined process before being approved for 
therapeutic purposes, but standard scientific scrutiny has been by-passed in the case of cannabis, 
which has been approved with a variety of indications [1-4]. It is therefore important to collect 
further objective data concerning the benefits and risks of using medical cannabis in order to be 
able to counsel patients and provide appropriate clinical c re. 
This review will concentrate on the use of medical cannabis and cannabis-based medicines in 
managing rheumatic conditions, and highlight the aspects that we believe to be relevant to clinical 
practice. 
 
2.Legality of Cannabis 
The possession of Cannabis is considered a non-criminal offence in many Western countries, while 
it is punished or may be punished by prison in countries in the Middle East and Asia. On the other 
hand, the recreational use of cannabis has been legalized throughout Uruguay, Luxembourg 
and Canada , in the District of Columbia and in ten states in the USA, and it is sold under license in 
Spain and The Netherlands.  
The medical use of cannabis has been legalized in Australia, Canada, Chile, Colombia, Finland, 
Germany, Greece, Israel, Italy, The Netherlands, Norway, Peru, Poland, and Thailand [5], as well as 
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in the District of Columbia and 33 states in the USA. In other countries only certain cannabis-
derived pharmaceutical drugs such as Sativex, Marinol or Epidiolex to be used. 
 
3.THE ENDOCANNABINOID SYSTEM 
Endocannabinoids (eCBs), their receptors, and the associated mediating enzymes for synthesis and 
degradation comprise the endocannabinoid system (ECS) (Figs. 1,2 ).  
Trans-Δ9-tetrahydrocannabinol (THC, the primary psychoactive constituent of cannabis) was first 
isolated in the 1960s [6,7], and the identification of cannabinoid receptors 1 and 2 (CBr1 and CBr2) 
led to the isolation and characterization of their endogenous ligands, the endocannabinoids 
N-arachidonoyl-ethanolamine (AEA, also known as anandamide), 2-arachidonoylglycerol (2-AG), 2-
archidonoylglyceral ether (noladin ether), O-archidonoyl ethanolamine (virodhamine) and N-
arachidonoyl dopamine.  Five main enzymes are involved in their biosynthesis and inactivation: 
N-acyl-phosphatidylethanolamine-hydrolysing phospholipase D (NAPE-PLD), sn-1-specific 
diacylglycerol lipase-α (DGLα), DGLβ, fatty acid amide hydrolase 1 (FAAH), and monoacylglycerol 
lipase (MAGL, also known as MGL) [8-10].  
3.1 Cannabinoid receptor 1 
The human cannabinoid 1 (CBr1) receptor, which is a G protein-coupled receptor, is part of the 
endocannabinoid system (ECS), which is highly regulatory in various functions throughout the 
body. CBr1 is widely distributed in the brain and is predominantly expressed on axons and 
presynaptic terminals [11-13]. 
The primary psychoactive component of cannabis, delta-9-tetrahydrocannabinol (THC), binds to 
CBr1, and this binding in the CNS is responsible for the psychoactive effects of cannabis.  
The effects of CBr1 on the brain are predominantly facilitated by retrograde signalling (also called 
retrograde neurotransmission) induced by post-synaptic cell depolarization; this leads to the post-
Ac
ce
pte
d M
an
us
cri
pt
 
 7
Information Classification: General 
synaptic production and release of endocannabinoids, which activate pre-synaptic CBr1. CBr1 
activation has an inhibitory effect on pre-synaptic cells (Fig. 1).  
The deconstruction of CBr1 signaling reveals various molecular pathways. Acting via Gi/o proteins, 
CBr1 activation inhibits adenylate cyclase, reduces cell cAMP levels and, subsequently, decreases 
the inhibitory activity of protein kinase A (PKA), which increases the activity of A- type potassium 
channels and leads to an overall decrease in cell potassium levels [12-13]. 
Another route of CBr1 signaling is via the βγ subunit of G protein-coupled receptor, which 
activates mitogen-activated protein kinase (MAPK) and phosphoinositide-3-kinase. The activation 
of CBr1 also has contrasting effects on cell ion channels as it stimulates inward-rectification [12-
13]. 
CBr1 is also expressed in other tissues, organs like the thyroid and adrenal gland, liver, adipose 
tissue, the gastrointestinal tract, and the reproductive organs, as well as on immune cells. An 
immunosuppressive function via CBr1 was shown by endogenous and exogenous cannabinoids in 
several studies [13-19].  
Its expression in the brainstem is relatively low, which may account for the limited toxicity of 
cannabis and the absence of respiratory suppression [20]. 
CBr1 are also found on the chondrocytes and osteocytes of human joints and there is evidence 
suggesting that CBr1 facilitates the adhesion of fibroblast-like synoviocytes (FLSs) to fibronectin, 
thus reducing the migratory capacity of these cells and possibly decreasing cartilage destruction 
[21]. 
3.2 Cannabinoid receptor 2 
CBr2 (also known as the peripheral cannabinoid receptor) is another G protein-coupled receptor 
that has a 44% amino acid similarity with CBr1. It acts in a similar manner to CBr1 by inhibiting 
adenylate cyclase and activating MAPK, but its activation can also transiently increase intra-
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cellular calcium levels via phospholipase C [22,23]. It is primarily expressed on immune cells, but is 
also expressed on chondrocytes, osteocytes, fibroblasts, FLSs, dorsal root ganglia, and microglial 
cells, although the extent to which it is expressed in the human nervous system is still unclear 
[18,20,21].  
Evidence of CBr2 mRNA has been found in rodent cerebellum, cortex, brainstem, spinal cord and 
glial cells, and it is worth noting that the Q63R variant is associated with autoimmune diseases 
such as celiac disease, immune thrombocytopenic purpura, and (of particular interest to 
rheumatologists) juvenile idiopathic arthritis [23]. 
3.4 Other cannabinoid receptors 
While It is agreed that CBr1 rand CBr2 are the two main cannabinoid receptors, but there is still 
debate concerning the identity of others[24], including:  
• Transient receptor potential cation channel subf mily V member 1 (TRPV1) is a ligand-
activated cation channel that is mainly regarded as a pain receptor [25]. 
• G protein-coupled receptor 55 (GPR55) is sometimes referred to as a candidate ‘CB3’ 
receptor. [2,24,26]. 
• Peroxisome proliferator-activated receptor-α (PPARα) is a fatty-acid-activated 
transcription factor that is predominately expressed on skeletal muscles, but also in the 
liver (it is the designated site of action of fibrates, the fibric acid derivatives used to treat 
hypercholesterolemia) and on human chondrocytes and osteocytes [26]. 
 
3.5 Phytocannabinoids 
The cannabis plant contains over 400 naturally occurring chemicals and approximately 100 
phytocannabinoids (Fig.3) [27-29].  Cannabis is the root word and the scientific plant genus from 
which all other names derive. There are 3 subspecies of cannabis, including Cannabis sativa, 
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Cannabis indica, and Cannabis ruderalis. Cannabis sativa [28] is the most widely cultivated plant 
for both commercial and pharmaceutical use.  The best known among phytocannabinoids are Δ9-
tetrahydrocannabinol (THC) and cannabidiol (CBD), which are already being used in medicine: Δ9-
THC is considered to be the main psychoactive component of C. sativa because of its high affinity 
with and partially agonistic effect on CBr1, whereas CBD is the main non-psychoactive component 
and is characterised by a relatively low affinity for cannabinoid receptors [29]. CBD acts as a partial 
antagonist of CBr1 and a weak inverse agonist of CBr2, although it can indirectly activate both by 
increasing AEA and 2-AG levels. It is thought that THC and CBD have synergistic effects in which 
other phytocannabinoids may participate, and this has given rise to the theory of an ‘entourage 
effect’ that increases the benefits of cannabis over synthetic cannabinoids [30].  
The components that may contribute to the entourage effect are the terpenoids and flavonoids. 
The former shares a common precursor with phytocannabinoids and give cannabis its distinctive 
aroma, but also induce medicinal effects (attributed to their anti-inflammatory properties) and 
have modulatory effects on THC. Cannabis leaves consist of ~1% flavonoids, and apigenin and 
quercetin are the main flavonoids found in cannabis [29]. Some flavonoids may have anti-arthritic 
properties as arthritic mice trea ed with a flavonoid extract from the Daphne genkwa plant 
containing 29.51% apigenin had significantly lower arthritis scores than controls [31,32]. 
 
3.6 Medical Cannabis and Cannabis-based medicines 
Some confusion has arisen because the simple word “cannabis” is used to describe both the drug 
of abuse unlawfully sold on the street, and the plant and plant-based products used for 
therapeutic purposes. It is therefore more appropriate to use the term “medical cannabis” in the 
case of cannabis plants and plant material, and the terms ‘cannabis-derived’ or ‘cannabis-based’ 
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medicines in the case of medicinal cannabis extracts whose THC and THC/CBD content have been 
standardized and defined. 
Furthermore, the fact that oils and extracts containing small or not clearly specified amounts of 
CBD can be legitimately sold as “nutritional supplements” has only added to the confusion. 
 
3.7 Synthetic and semi-synthetic cannabinoids 
Excluding off-the-shelf cannabinoid supplements, three cannabinoid products (synthetic 
cannabinoids and phytocannabinoids) have been approved for medical use. Nabiximols is the only 
one that consists of natural THC and CBD extracted from cannabis, whereas dronabinol being 
plant-derived but chemically modified during extraction, is considered a synthetic THC, and 
nabilone is a synthetic cannabinoid resembling THC [33,34]. 
Dronabinol (Marinol) is the main isomer of tetrahydrocannabinol, the main psychoactive 
constituent of the marijuana plant (Cannabis sativa) [35].   It is a partial agonist of the cannabinoid 
receptors in the central nervous system (CB1) and periphery (mainly CB2). Activated CB receptors 
have effects on appetite, mood, cognition, memory and perception,.  The current indications of 
dronabinol, which was approved for use in the United States in 1985 and is available generically 
and under the brand name Marinol in the form of 2.5, 5 and 10 mg capsules, are anorexia with 
weight loss in AIDS patients, and the prevention of cancer chemotherapy-associated nausea and 
vomiting.  There is no convincing, unbiased, high quality evidence suggesting that cannabinoids 
are of value for anorexia or cachexia in cancer or HIV patients. An overview of systematic reviews 
of RCTs concluded that, with safe and effective antiemetics available, CBs can be recommended as 
a third-line treatment in the management of breakthrough nausea and vomiting but, given the 
lack of RCT data and safety concerns, herbal cannabis cannot be recommended for CINV. The 
typical twice-daily adult oral dose of 2.5 mg can be increased up to 20 mg/day depending on 
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tolerability and effect. The most frequent side effects are drowsiness, fatigue, dizziness, 
conjunctivitis, abnormal thinking and paranoid reactions, euphoria, nausea, vomiting, abdominal 
pain and diarrhea; hallucinations and seizures are rare side effects include [33,34].  
Namisol® is the world’s first oral tablet containing fixed doses of pure natural Δ9-THC (dronabinol) 
that ensure a predictably high level of bioavailability and a long and stable shelf life at room 
temperature. It is due to be registered for a number of indications, including MS, behavioural 
disturbances in patients with Alzheimer’s disease, and chronic pain [28,33,36].  
Nabilone (marketed as Cesamet in Canada, Mexico, the UK and the USA) is a synthetic 
cannabinoid that is therapeutically used as an anti-emetic and adjunctive analgesic for 
neuropathic pain. It mimics the main ingredient of THC, but has more predictable side effects and 
causes minimal or no euphoria. It was approved by the American Food and Drug Administration 
(FDA) for the treatment of CINV not responding to conventional anti-emetics in 1985, but was not 
marketed for this use until 2006; it is also approved for the treatment of anorexia and weight loss 
in patients with AIDS. Although only Mexico and Belgium have  officially approved the indication, it 
is currently widely used as an adjunct in the management of chronic pain, although trials and case 
studies have shown conflicting results on potential benefits in conditions such as fibromyalgia and 
multiple sclerosis (MS) [29,33].  
Nabiximols (trade name Sativex) is a cannabis extract approved in the UK in 2010 as a botanical 
mouth spray designed to alleviate neuropathic pain, spasticity, an overactive bladder, and other 
symptoms of MS. It has a standardised composition, formulation and dose, and its main active 
cannabinoid components are THC and CBD; each spray delivers 2.7 mg of THC and 2.5 mg of CBD 
[28,33-35]. 
 
3.8 Natural cannabinoids 
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Many types and strains of medicinal cannabis (with THC and CBD contents of respectively 1-22% 
and 0.05-9%) can be prescribed in different European countries [33]. Table 1 shows the main 
natural cannabinoids available in Italy. The leaves and flowers contain many molecules, of which 
THC and CBD are the most studied. In addition to THC and CBD, herbal cannabis contains many 
non-cannabinoid molecules, with physiologic effects that are largely unknown. 
Medical cannabis refers to the whole plant or extract thereof, used for medical purposes as dried 
flowers and leaves or an oil extract, and may be administered by smoking, inhalation through a 
vaporizer (heating to lower temperatures than smoking), ingestion, or topical applications. 
Cannabinoids are also available as pharmaceutical quality preparations, either as plant extracts 
with specified doses of THC and CBD, or synthesized products acting on cannabinoid receptors 
[36]. The choice may depend on age, co-morbidities, tolerance, pathology and symptomatology.  
Of all the different routes of administration (oral, topical, rectal, vaginal, sublingual,  inhalation), 
the oral and the inhalation by vaporization routes are the most used. Both methods  provide for 
the heating of cannabis, an operation necessary for the decarboxylation (total or partial) of 
cannabinoids contained in plant derivatives. 
Depending on the route and the form of administration, various modifications can be made to the 
chemical composition of cannabis and, consequently, to the effect obtained [36]. 
Each mode of administration and formulation has its strengths and drawbacks [36-38]. The oral 
formulations available are capsules and liquid extract (tinctures, cannabis raw papers useful to be 
infused in drinks, oil), resin, edible (e.g. biscuits, chocolates, cannabis, juices, raw cannabis). The 
oral formulations of cannabis take at least 30 to 90 minutes before any effects are felt, reaching 
peak effect after 2-4 hours from intake. Given these properties oral administration is useful for 
chronic conditions requiring higher dosage and longer half-life; at the same time overdosing is 
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much more common than inhalation. For this reason, it’s important to allow at least three hours 
from one administration to another. 
Another disadvantage is that the delayed onset of action makes dose titration difficult and makes 
them little useful in some conditions e.g. nausea or muscle spasm that require rapid onset of 
action. In this case, oro-mucosal or sublingual administration are preferable because of their faster 
action and uptake; formulations available are lozenges, lollipops, drops, oil and spray pump.  
The extract in oil  is a very concentrated medicine and it is the easiest to dose and the most 
practical in the intake. It involves the extraction in the laboratory by means of oily solvent of the 
active ingredients starting from the inflorescences. There are different methods of extraction, 
which influence the concentration of the final product. The preparation using the Roman and 
Hazekamp method involves a hot extraction by olive oil, with a solvent cannabis ratio of 1:10 (5-
10g of Cannabis in 50-100 ml of olive oil.) The process involves grinding Cannabis with a grinder to 
obtain a finer raw material and to increase the surface of contact with the solvent and to facilitate 
its action. The cannabis is added to the olive oil, heated to 98 ° C in a water bath for 120 minutes, 
cooled down and filtered under pressure to recover the oil of which the Cannabis remains 
impregnated. Different types of Cannabis can be used with this method.  
Oil type, heating times, techniques and extraction mechanics can vary with variable oil 
concentrations. 
The resin obtain by the described method is generally dispensed in 1 ml syringes and it is black for 
the presence of chlorophylls. The dosage is extremely variable: generally the minimum dose is a 
drop, increasing by approximately 1 drop every 3-4 days, evaluating any side effect or the 
appearance of psychotropic effects, nausea, vomiting or loss of appetite.  The heating of the plant 
at 200 C° reached with the vaporization allows the liberation of the cannabinoids and terpenes in 
the form of vapor, their rapidly absorption by the lungs and distribution in the whole body.  
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The effect is rapid but not lasting, indeed first effects occur within 90 seconds and reach a 
maximum after 15-30 minutes, wearing off in 2-4 hours.  For this reason vaporizing cannabis 
products is best in acute conditions where rapid relief is required. Inhaled administration requires 
a vaporizer and there are a wide variety of vaporizers commercially available. The Volcano is 
approved as a medical device. 
The recommended operating temperature of the device is about 210 ° C: this allows the emission 
of a barely visible steam (a light mist) and the extraction of all cannabinoids, representing the ideal 
balance between aroma and quantity extracted. Technically it is possible to use the vaporizer at 
different temperatures (e.g. 190 ° C or 230 ° C), thus changing the quantity and type of substances 
extracted. It is recommend starting with one or two vaporizations per day, with an interval of 5 to 
10 minutes between one inhalation and another. After about 1 week a constant concentration of 
active ingredients is reached and the dosage can be reassessed if it proves unsatisfactory.  
The topical formulations comprise eye drops, gel and cream. 
The cannabis eye drops are an oil-based drug which, once prepared, is cold sterilized by means of 
micropore filtration under a sterile laminar flow hood. A very small percentage of surfactant is 
added to it to make the oil adhere better to the water. 
Usually, 1-2 drops per eye are applied, one or more times a day according to medical prescription. 
The main side effects are related to the initial burning that can be felt due to the acidity of the oil; 
generally it disappears in a few seconds and after a few weeks of use, it tends not to appear 
further. It must be shaken energetically 5-6 times each time before being administered, to favor 
the re-solubilization of eventual formations of zones of different concentration. Transdermal gel  is 
an innovative and experimental approach to cannabis intake at the local level (on the skin) and 
systemic, since the gel is transdermal, which prefers a high absorption of substances to reach the 
blood vessels and, from there, all the body. Being an experimental drug, the precise amounts 
Ac
ce
pte
d M
an
us
cri
pt
 
 15
Information Classification: General 
absorbed are not yet known. The main side effect can be as follows: redness or itching in the area 
of application (rare) [39]. 
The dosage of Cannabis derivatives is extremely variable and depends on numerous factors that 
contribute to determining the dosage (sex, age and weight of the patient, nature of the disease, 
type and severity of symptoms, concomitant therapies, route of administration) Therefore dosing 
is highly individualized and relies on titration of the product [40]. 
The first problem in the choice of dosage is to try to standardize the dosage by disease. This 
approach is found to be unsuccessful in the case of cannabis because it is not administered as a 
drug with only one active ingredient, but hundreds of substances that act in synergy. 
Using the premise ’starting low and going slow’ Cannabis dose should be increased gradually until 
the prescribed optimal dose, where therapeutic effect is maximized and adverse effects are 
minimized, is reached. Although the methods of consumption most commonly used are 
vaporization and smoking of cannabis we strongly contraindicate them because of the high 
variance of bioavailability, the short-term supratherapeutic plasma levels and the possible 
carcinogenic effects.  
The regulatory frameworks normalizing the dispensing of cannabis and cannabinoids for medical 
purposes and the processes that led to their promulgation are different among various nations 
[41]. Since the chemist Raphael Mechoulam identified Tetahydrocannabinol (THC)  in the early 
1960s, Israel has always represented a pioneering country adopting a constantly evolving policy to 
allow the medical use of cannabis and cannabinoids. The Israeli system is an example of synergy 
between government, physicians, cannabis growers and suppliers and patients. Under the control 
of Israeli Medical Cannabis Agency (IMCA) a unit within the Ministry of health, Israel was one of 
the first countries to legalized the medical use of cannabis. The IMCA controls the production of 
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cannabis and authorizes some cultivators, that must follow the indications of IMCA guide  ‘Medical 
Grade Cannabis Cannacopeia,  to supply it to authorized pharmacies. 
The cannabis is distributed in two forms : as an oil  for oral intake or as dried flowers for smoking 
or vaporization. The number of physicians authorized to prescribe ( at present are 30) for these 
indications are limited. 
In Canada, the legalization process of medical cannabis started in 2000 and has changed over the 
years under pressure of patients and court pronouncements. Since 2014, more growers of 
cannabis have been authorized and more prescription freedom has been given to medical and 
nurse practitioners; federal supervision has been removed and patients are allowed to buy 
cannabis directly from authorized producers. In this way the responsibility for the use of medical 
cannabis has been transferred to the medical community. 
At the same time, the Canadian Parliament is engaged in n awareness campaign against possible 
damage related to recreational use of cannabis and in 2018 it approved the Cannabis Act (Bill C45)  
to legalize and regulate this use. 
In Italy, with ministerial decree 23/01/2013, the use of cannabis for therapeutic purposes was 
made official and included in Table II, section B, among the drugs of plant origin. Successive 
decrees of 2015 and 2016 have regulated the cultivation and preparation of derived products, 
defined the costs and production quotas and the pathologies for which their use is allowed. 
The reimbursement to be paid by the National Health Service is subject to the indications of the 
individual regions. 
Each specialist is qualified for prescription, which must be drawn up according to specific 
regulations. A prescription should only be provided by a physician who is fully knowledgeable of 
the patient and is responsible for patient care. The medical encounter must include 
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documentation of the medical condition, reason for medical cannabis consideration, associated 
comorbidities, current medications, and previous treatment trials.  
 
The varieties of medicinal cannabis prescribed in Italy are listed in Table 1. FM2 cannabis produced 
by the military pharmaceutical plant in Florence consists of unfertilized, dried and ground female 
inflorescences with particles smaller than 4 mm, containing acid precursors of delta-9-
tetrahydrocannabinol (THC) corresponding to a percentage of THC between 5 and 8% and 
cannabidiol (CBD) corresponding to 7.5 - 12%. 
Cannabis should not be smoked, because of the toxic products of combustion. Inhalation through 
a vaporizer is preferred, because less intensive heating reduces release of toxic combustion 
products. Inhaled cannabis, through a vaporizer, will give effects within a few minutes, with 
effects lasting up to a few hours, although the psychoactive and motor effects may last for over 24 
h. The effects of ingested cannabis will occur more slowly and be more prolonged, and may be the 
preferred method of administration for a treatment regimen. Although there is no evidence to 
support the therapeutic effect of various concentrations of THC and CBD in the herbal product, 
cannabis with a low THC content and higher CBD content is preferable because there will be fewer 
and less severe THC-induced psychoactive effects. Studies to date have reported on THC content 
up to 12.5%, but with a high rate of adverse events at this concentration.[42] 
The ideal dosing schedule for medical cannabis is unknown, with no dose-finding studies to 
examine optimal daily amount or specific molecular concentrations of THC and CBD6. Some 
patients may choose “on-demand” use rather than regular use, but there is no evidence to 
support this method. 
 
4.THE USE OF CANNABIS IN RHEUMATIC DISEASES 
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4.1 Rheumatoid arthritis 
Rheumatoid arthritis (RA) is still a major health burden that affects quality of life and consumes 
healthcare resources; it can cause pain, joint malformations and joint destruction, and is one of 
the main causes of disability worldwide [43]. The anti-inflammatory effects of Cannabinoids have 
been shown in animal models of arthritis [44]. According to in vitro studies, cannabinoids reduce 
cytokine production by RA fibroblasts as well as the release of matrix metalloproteinases (MMPs) 
from fibroblast-like synovial cells (FLSc) [45-47]. Cannabinoids have also been shown to reduce 
interleukin 1 (IL-1) induced proteoglycan and collagen degradation in bovine cartilage, thus 
reducing cartilage extracellular matrix (ECM) breakdown [48]. One study has found AEA, 2-AG, CB1 
and CB2 protein and mRNA expression in synovial tissue obtained from 13 RA patients undergoing 
arthroplasty, whereas synovial tissue obtained from healthy volunteers was negative for AEA and 
2-AG [49].  
The precise role of the cannabinoid system is still unclear, but these findings suggest that 
cannabinoids could potentially be used in the treatment of RA (49). In a separate study of synovial 
tissue taken from RA patients, the production of IL-6 and IL-8 by stimulated synovial cells was 
attenuated by low concentrations of WIN 55,212-2 mesylate, and high concentrations led to their 
CB2-dependent inhibition [50]. These results are supported by various in vivo and in vitro 
experimental studies. Three research groups have used a murine model of collagen-induced 
arthritis (CIA) and observed clinical improvements after treatment with various cannabinoids: 
exposure to cannabidiol or the CB2 agonists JWH-133 or HU-308 reduced disease severity, 
inflammatory cell infiltration, bone destruction, the production of anti-collagen type II IgG1 and 
IFNγ, and the release of TNF [51-53]. 
Furthermore, a 5-week study of 58 patients found that nabiximols oromucosal spray was 
significantly superior to placebo and significantly improved pain on movement and at rest, DAS28 
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and SF-MPQ pain scores, and the quality of sleep. Most of the adverse effects were mild or 
moderate, none of them was serious, and none led to treatment discontinuation [54].  
No randomized clinical trials (RCTs) of other cannabis-based medicines are available. 
 
4.2 Osteoarthritis 
Osteoarthritis (OA) is a high prevalent rheumatic disease but treatment is mainly based on 
analgesia because no disease-modifying intervention has yet been discovered [55]. OA seems to 
be the most frequent rheumatic disease treated with cannabis [56,57], The endocannabinoid 
system may be a therapeutic target as both CBr1 and CBr2 are expressed in osteoarthritic synovia, 
and 2-AG and AEA have been found in the synovial fluid of OA patients but not in that of healthy 
volunteers [49]. In line with these findings, CBr1 and CBr2 are also expressed in the chondrocytes 
of patients with OA [56]. The possibility of using cannabinoids in the treatment of OA is further 
supported by the results of a 2015 study of a murine model of surgically induced OA 
(destabilisation of the medial meniscus) in which the mice treated with the CBr2 agonist HU-308 
showed milder disease than those treated with vehicle, and CBr2-deficient mice had a more 
severe form of OA than their wild- ype counterparts [58]. 
Various mechanisms have been suggested to explain the possible therapeutic effects of 
cannabinoids. Exposure of OA chondrocytes to WIN 55,212-2 mesylate [56,59] reduced the activity 
of metalloproteinases and nitric oxide production in bovine chondrocytes [57]. Another possible 
pathway is chondrocyte apoptosis as it has been shown that AEA decreases the viability of murine 
chondrocytes, and thus potentially contributes to cartilage destruction [60]. 
4.3 Systemic lupus erythematosus Systemic lupus erythematosus (SLE) is a chronic autoimmune 
disease characterized by various clinical manifestations that can involve different organs and 
systems [61]. Key features of SLE seem to be the abnormal formation of extracellular neutrophil 
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traps, defects in apoptotic clearance, and a type 1 interferon (IFN) signature, which can lead to a 
loss of tolerance and consequent B and T lymphocyte abnormalities [62,63]. 
A recent study has found that plasma 2-AG levels are significantly higher in SLE patients than in 
healthy subjects (p=0.0059). and that the patients with the highest levels had less active disease; 
there were no between-group differences in the concentrations of N-arachidonoylethanolamine 
(AEA) or its congeners N-palmitoylethanolamine (PEA) and N-oleoylethanolamine (OEA). A gene 
expression analysis of metabolic enzymes and the receptor targets of eCBs, and an investigation of 
the functional activity and protein expression of selected components of the eCB system, revealed 
that the expression and functional activity of the 2-AG biosynthetic enzyme DAGL were selectively 
enhanced in the PBMCs of the patients. This study demonstrates for the first time that SLE 
patients have an altered ECS [64], and it is interesting to note that modulating CBr2 expression 
certainly provides a biochemical and molecular basis justifying a planned phase II clinical trial 
(NCT03093402) designed to evaluate the efficacy, safety and tolerability of a new and highly 
purified composition of ajulemic acid (a synthetic non-psychoactive cannabinoid) in SLE patients 
[65]. 
 
4.4 Systemic sclerosis 
Systemic sclerosis(SSc) is an immune-mediated, rare, systemic disease with an unknown etiology, 
characterised by excessive fibrosis, extra-cellular matrix deposition, and vasculopathy also known 
as scleroderma to emphasize the hard appearance taken on by the skin [66]. It has a high 
morbidity and mortality mainly related to visceral involvement [67]. 
One of the pathways being explored in SSc treatment research is the endocannabinoid system. It 
has been shown that CBr1 and CBr2 modulate SSc in various murine models. CBr1 activation 
seems to exacerbate fibrosis, and CBr1-deficient mice show decreased dermal thickening [68]. 
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Unlike CBr1, CBr2 may protect against SSc: CBr2-deficient mice injected with bleomycin show 
increased dermal thickness and have higher leukocyte counts in skin lesions, and treating wild-
type mice with the CBr2 agonist JWH-133 reduces leukocyte infiltration and dermal thickening 
[69]. Similar results have been obtained in mice treated with VCE-004.8, a dual agonist of PPARγ 
and CBr2 that reduces dermal thickness, collagen accumulation in blood vessels, skin macrophage 
infiltration, and mast cell degranulation [70]. JHW-133 also prevents the development of skin and 
lung fibrosis and reduces anti-DNA topoisomerase antibody levels and fibroblast proliferation in a 
murine model of hypochlorite-induced fibrosis [71].  
CBr2 may potentially be a key modulator of fibrogenesis. Wounded mice treated with the CBr2 
agonist GP1a showed reduced fibroblast accumulation, fibroblast-to-myofibroblast transformation 
and collagen deposition, and lower levels of transforming growth factor-β1 (TGFβ1), IL-6, TNF and 
vascular endothelial growth factor [72,73]. 
In comparison with fibroblasts from healthy subjects, analyses of biopsied human skin reveal an 
over-expression of CBr1 and CBr2 in the fibroblasts of patients with diffuse cutaneous 
SSc   (dcSSc), and treating the fibroblasts with WIN 55,212-2 mesylate decreased extra-cellular 
matrix deposition, myofibroblast differentiation, and resistance to apoptosis [73,74]. 
Lenabasum (JBT-101) is a selective cannabinoid receptor type 2 agonist which is undergoing 
clinical investigations for the treatment of systemic sclerosis (the RESOLVE-1 trial - NCT03398837) 
as well as in additional rheumatological conditions such as dermatomyositis (NCT03813160) and 
SLE (NCT03093402).  Thus, selective cannabinoid receptor agonists may gain an increasing future 
role as targeted treatment for systemic autoimmune disorders.  
 
4.5 Fibromyalgia (FM) 
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FM is a chronic syndrome of unknown pathophysiology that is characterized by widespread pain, 
morning stiffness, fatigue, sleep and emotional disturbances and cognitive dysfunction [75]. It has 
been suggested that it may be related to the suppression of descending inhibitory pathways, 
central sensitization, excessive glial cell activity, abnormal neurotransmitter release, and/or an 
abnormal stress response [76]. Currently, the treatment is based on the relief of symptoms but 
poor results are achieved. Given its unknown pathophysiology and the absence of suitable 
treatment, cannabis (which is frequently used for analgesic purposes) is a natural therapeutic 
candidate, and its medicinal use for FM has been approved in a number of countries. [77-84]. 
All of the clinical trials investigating the effectiveness of cannabinoids in the treatment of FM have 
used nabilone. A placebo-controlled study of 40 FM patients investigated the results of four 
weeks’ treatment with nabilone. The authors reported that nabilone led to a statistically 
significant improvement in pain relief in pre- and post-treatment comparison [84], but a re-
analysis of the mean values and standard deviations described in the paper found that there was 
no statistically significant difference [91]. Furthermore, another study of 32 patients found no 
statistically significant difference between nabilone and amitriptyline in terms of reduced pain 
after two weeks [85].  
However, as the small sample sizes and short duration precluded unbiased conclusions, the 
studies did not support the use cannabinoid treatment for FM [83]. On the contrary, a US 
government-sponsored committee concluded that there is moderate-grade evidence supporting 
the effectiveness of cannabinoids [86]. 
One observational study that did not meet the inclusion criteria for the Cochrane review 
compared 28 FM patients who used cannabis with 28 who did not. Two hours after cannabis self-
administration, the cannabis users reported a reduction in pain and stiffness and increased 
relaxation, accompanied by greater somnolence, feelings of well-being, and SF-36 mental health 
Ac
ce
pte
d M
an
us
cri
pt
 
 23
Information Classification: General 
component scores; however, there were no improvements in the other components of the SF-36, 
in FIQ scores, or in the Pittsburgh Sleep Quality Index [87]. 
An experimental, randomized, placebo-controlled, 4-way crossover trial investigated the analgesic 
effects of inhaled pharmaceutical-grade cannabis in 20 FM patients suffering from chronic pain 
[88]. They received four different cannabis varieties whose THC and CBD contents were known: 
Bedrocan (THC 22.4 mg, CBD <1 mg; Bedrocan International BV, Veendam, The Netherlands), 
Bediol (THC 13.4 mg, CBD 17.8 mg; Bedrocan International BV, Veendam, The Netherlands), 
Bedrolite (CBD 18.4 mg, THC <1 mg; Bedrocan International BV, Veendam, The Netherlands), and a 
placebo without any THC or CBD. Plasma THC and CBD concentrations, the thresholds of pressure 
and electrical pain, spontaneous pain scores, and drug highs were measured for three hours after 
a single inhalation of vapor. None of the treatments had more than a placebo effect on responses 
to spontaneous or electrical pain, but Bediol showed n additional 30% pain decrease over 
placebo (90% vs 55%, P=0.01), and the spontaneous pain scores correlated with the extent of the 
drug highs (ρ = -0.5, P<0.001). The cannabis varieties containing THC significant increased pressure 
pain thresholds in comparison with placebo (P<0.01). CBD inhalation increased plasma THC 
concentrations, but reduced the analgesic effects induced by THC, thus indicating synergistic 
pharmacokinetic but antagonistic pharmacodynamic interactions. The trial showed the complex 
behavior of inhaled cannabinoids in chronic pain patients, with just a small analgesic response 
after a single inhalation, but there is a need for further studies in order to determine the long-
term effects of treatment on THC-CBD interactions and spontaneous pain scores, and the role of 
psychotropic symptoms in relieving pain [89]. 
Many FM patients suffer from low back pain (LBP), and a recent observational cross-over study of 
such patients has assessed the possible improvement in pain and function associated with medical 
cannabis therapy (MCT). Thirty-one patients received standardized analgesic therapy (SAT: 
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oxycodone hydrochloride 5 mg [equivalent to oxycodone] and naloxone hydrochloride 2.5 mg 
twice daily and once-daily duloxetine 30 mg) for three months, after which they could choose to 
be given MCT for a minimum of six months. The patient reported outcome (PRO) instruments 
were the revised Fibromyalgia Impact Questionnaire (FIQR), a visual analog scale (VAS), the 
Oswestry Disability Index (ODI) and the 12-item Short Form Survey (SF-12), and their lumbar range 
of motion (ROM) was measured using the modified Schober test. SAT led to a minor improvement 
from baseline, but the addition of MCT significantly improved all of the PROs after three months, 
and the effect was maintained for up to six months. ROM also improved after three months of 
MCT and continued to improve after six months [90]. These results show that MCT has an 
advantage over SAT in FM patients with LBP, but further randomized clinical trials are needed to 
establish whether these can be generalized to the FM population as a whole [90]. 
No RCTs of other cannabis-based medicines are available. 
In table 2, the possible mechanism of cannabinoid action in different rheumatic conditions are 
summarized. 
5. Adverse events 
In the literature, there are a limited number of studies on adverse events associated with the use 
of therapeutic cannabis [91]. Most of the data come from studies related to recreational use. 
Furthermore, while there is some information on short-term side effects, there is much less 
information on the long-term consequences.  A two-fold higher rate of non-serious adverse events 
in patients using medical cannabis compared to controls was described in a Canadian systematic 
review [92]. The data on short-term effects of medical use of cannabinoids and cannabis have 
been collected from randomised controlled clinical trials in different medical conditions conducted 
usually for periods of 8 to 12 weeks. The adverse events reported were usually minor and the 
most frequent was dizziness. Other adverse events frequently described were nervous system 
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disorders, psychiatric disorders, gastrointestinal disorders and vascular and cardiac disorders. 
Another important consideration in the estimation of adverse effects related to cannabis use is 
the concomitant use of tobacco, alcohol and other drugs. 
Table 3 and 4 report the major adverse effects of the medical use of cannabis and cannabinoids. 
Table 5 describes the possible interaction with other pharmacological products. 
5.1 Cardiovascular effects 
Tachycardia and hypotension are common adverse events related to the use of cannabis and in 
patients with heart disease could compromise their cardiovascular status. A temporal relationship 
has also been shown between acute cannabis use and increased risk of myocardial infarction and 
reduction of exercise competence in patients with angina pectoris.  
 
5.2 Cancerogenesis 
Starting with the evidence that cannabis smoke condensates contain many of the same chemicals 
as tobacco smoke, some in vitro studies have shown strong evidence that smoke cannabis is 
carcinogenic and, lately, a comparison regarding the cytotoxic and mutagenic potential effects of 
cannabis smoke condensates and their tobacco equivalent has shown a higher risk for cannabis 
smoke. 
Evidence from in vivo studies are conflicting but despite these it is suitable to discourage cannabis 
smoke. One study has assessed the relationship among cannabis use and testicular cancer [93]; a 
large population-based case-control study, it didn’t find a significant relationship between 
cannabis use and lung cancers. 
 
5.3 Pregnancy and breastfeeding 
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An increased risk of some congenital birth defects may be associated with its use during early 
pregnancy, although THC does not seem to show significant teratogenic effects [94].  Human and 
animal neurodevelopmental data suggest that prenatal exposure to THC may lead to subtle but 
persistent changes in targeted aspects of higher-level cognition and psychological well-being [95]. 
Consequently, pregnant women or women considering pregnancy should be encouraged to stop 
using THC for medicinal purposes in favor of an alternative treatment for which there are better 
pregnancy-specific safety data. 
There are only limited and inconsistent data concerning the presence of the constituents of 
cannabis-based medicines in human milk, or their effects on milk production or breastfed infants. 
Breastfeeding should be discouraged during treatment with cannabis-based medicines [96]. 
Early, frequent and heavy recreational use of cannabis during adolescence has been associated 
with poor cognitive and psychiatric outcomes in adulthood [97-99], but no definite conclusions 
can be drawn as to whether its use alone negatively affects human adolescent brains. Children and 
adolescents should only be treated with cannabis-based medicines in exceptional cases. 
In conclusion the frequent adverse events related to pharmaceutically prepared cannabinoid 
treatments are usually not serious, but may be sufficient to affect patient well-being. A meta-
analysis by Fitzcharles et al. has revealed that 25-50% of subjects experience side effects, mainly 
dizziness, drowsiness and some form of cognitive effect, and other studies have reported dry 
mouth, nausea and constipation. It is reassuring to note that none of the studies of cannabis-
based medicine have encountered any serious adverse events [100], but it must be noted that the 
development of a new class of agents designed to manipulate the endocannabinoid system 
[26,29,33,50], which includes selective synthetic cannabinoid receptor agonists or antagonists, 
inhibitors of catabolism (e.g. fatty acid amide hydrolase [FAAH] inhibitors), or the reuptake of 
endogenous cannabinoid ligands (endocannabinoids), may be  associated with more severe risks. 
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Presently, no clinical guidelines occur to monitoring patients who are taking cannabis for medical 
purposes so is necessary to carefully evaluated the risk/benefit ratio before prescribing medical 
cannabis.  Must be taken into account medical conditions, different variation in response and 
tolerance to its effects. Contraindications to cannabis use are shown in table 6. 
 
 
 
6. CONCLUSIONS 
It is currently difficult to recommend cannabis-based medicines for the treatment of patients with 
musculoskeletal pain and/or systemic autoimmune diseases, and there is still a need for larger, 
well-controlled clinical trials in order to clarify the potential benefits and risks; in fact, no definite 
conclusion can be drawn on the basis of meta-analyses [87,88,91] and of the available studies 
[114]. New pharmacological analgesics (including cannabis and cannabis-based drugs) can be 
helpful and should not be abandoned only because of prejudice and misconceptions. It is 
important to separate the recreational and medical use of cannabis in research, and in all 
discussions with patients and health authorities. Furthermore, although the debate is open, 
research is starting, and patients have important and relevant demands; however, the lessons 
learned from the opioid epidemic need to be remembered in order to avoid a cannabis crisis. 
In the face of patient demands, medical cannabis represents a challenge for physicians. About 75% 
of surveyed rheumatologists say that they lack confidence regarding cannabinoid treatment and 
consequently do not recommend it [100]. It is necessary to take into account possible adverse 
effects, interactions with other drugs, and the risk of addiction due to the unique characteristics 
and chronicity of rheumatic diseases, and the potential benefits of cannabinoid therapy must be 
weighed against these risks. Cannabinoids have various effects on immune cells that lead to an 
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overall anti-inflammatory effect, and their immunomodulatory properties are substantiated by 
studies of animal models of systemic rheumatic diseases, but their possible use in humans has 
hardly been explored. Surprisingly, despite the high prevalence of cannabis consumption and the 
fact that preliminary laboratory findings support cannabinoid treatment for rheumatic diseases, 
there is still a scarcity of clinical trials and, although some have been conducted in the field of RA, 
OA and FM, their small sample sizes and the inconsistencies of their findings prevent the drawing 
of definite conclusions and the formulation of recommendations. Furthermore, there seems to be 
a gap between the encouraging results obtained in animal models and the inconclusive results of 
clinical studies. 
 
7. Expert Opinion 
The possible therapeutic properties of cannabis have been known since ancient times. Over time, 
use as a medicine has been abandoned in favor of that for recreational purposes; only with the 
isolation in 1960s of D9 Tetraidrocannabinol, interest in medical cannabis has rekindled so much 
that the hottest question currently for clinicians is if it is possible to recommend cannabis as a new 
therapeutic option. 
First of all, it’s important to bring order to the confusion of terms between herbal cannabis, 
medical cannabis and cannabinoids. The term "cannabis" covers very different uses, including both 
illegal drugs and cannabis for medical use. The fact that low-cannabinol oils and extracts are 
proposed as nutritional supplements contributes to the confusion. 
 The term "medical cannabis" (or medical marijuana) should refer to the entire unprocessed 
marijuana plant or extracts for medical reasons and should be distinguished from cannabinoids 
which are natural, synthetic, semi-synthetic or plant-derived compounds, but always chemically 
composed such as 9-tetrahydrocannabinol (THC), cannabidiol (CBD), nabilone and Dronabinol. 
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An additive effect is shown by medical cannabis compared to pure extracts; no single active 
component of cannabis has this effect but the pharmacological action is probably related to the 
synergistic action of the different components (entourage effect). Cannabis can be consumed in a 
variety of different ways and although the most commonly used are smoking, vaporization and 
ingestion, we do not agree and contraindicate smoking and vaporization of medical cannabis 
because of the high variance of bioavailability and short-term supratherapeutic plasma levels . 
The lack of clinical evidence on the long-term side effects of cannabis use should be emphasized. 
The few existing clinical studies refer to the short term effects and the use of cannabis for 
recreational purposes. The most frequently reported adverse events were nervous system 
disorders, psychiatric disorders, gastrointestinal disorders and vascular and cardiac disorders. 
The current insufficient evidences do not allow recommending any cannabinoid preparation for 
rheumatology patients; so cannabis and cannabis-based medicines are not yet prescribed among 
health professionals and there are still conflicting positions in the professional association. 
The growing public opinion, which is pushing towards the legalization of the use of cannabis in 
chronic pain and various rheumatic conditions, makes it necessary to have educational programs, 
extended basic and clinical research that spread the correct knowledge into the mechanisms and 
clinical utility of cannabis and derivatives and their long-term side effects and allow a correct, 
rational and conscientious prescription from the medical community. 
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FIGURES LEGENDS 
Figure 1. Endocannabinoid system  
(1) Anandamide(A) and 2 Arachinodonoyl glycerol (2AG), the most know endocannabinoids,   are synthesized on-
demand tthrough the enzymatic hydrolysis of membrane precursors  and released in the intersynaptic gap 
immediately after production. The synthesis and release occurs following the increase of calcium. Thus released 
endocannabinoids can function as retrograde messengers by binding to presynaptic cannabinoid receptors,(2) which 
in turn inhibit the voltage-dependent calcium channels (Ca +) and activate those of potassium (K +) (3). This effect on 
membrane polarization involves an inhibition of the release of other neurotransmitters (such as glutamate, dopamine, 
GABA).(4) The neuromodulatory process of endocannabinoids ends with a re-uptake mechanism within neurons 
through a possible transporter(5) and subsequent degradation.(6) 
NAPE N-arachidonoylphosphatidylethanolamine(NAPE), PLD phospholipase-D, AA arachidonic acid, E ethanolamide, ,A 
Anandamide, FAAH fatty acid amide hydrolase enzyme,2 AG 2 Arachinodoyl glycerol, GLYC glycerol, MAGL 
monoacylglycerol lipase, FAAH fatty acid amide hydrolase, MAGL monoacylglycerol lipase, CB1 Cannabinoids 
receptors. 
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Figure 3. Pharmacological actions of the various cannabis Sativa compounds  
 
 
Δ9-THC
Psychoactive effects
CBN
(derived from ∆9-THC oxidation) 
Possible immunosuppressive
properties
(in vitro studies )
CBD
NO psychoactive effects
Possible anti- inflammatory, 
analgesic, anti-nausea, anti-emetic, 
anti-psychotic, anti-ischemic, 
anxiolytic, and anti-epileptiform
effects
CBG, CBC 
OTHER CONSTITUENTS
Nitrogenous compounds, amino acids, 
proteins, enzymes, glycoproteins, 
hydrocarbons, simple alcohols, 
aldehydes, ketones and acids, fatty
acids, simple esters and lactones, 
steroids, non-cannabinoid phenols, 
flavonoids, vitamins, and pigments
TERPENES
anti-oxidant; anti-anxiety, anti-inflammatory, anti-bacterial, anti-
neoplastic, anti-malarial (few in vitro and in vivo studies); 
responsible for differences in fragrance among cannabis plants, 
and may somehow modify or enhance the physiological effects of 
the cannabinoids. 
THCV 
NO psychoactive effects
anti-epileptiform/anti-convulsant
properties
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Abbreviations: CBD: cannabidiol; CBN: cannabinol; THCV: Tetrahydrocannabivarin; CBG: cannabigerol;  CBC: 
cannabichromene; ∆9-THC : Delta-9-tetrahydrocannabinol 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Varieties of cannabis and related THC and CBD concentrations, terpenic profile and 
countries of origin available in Italy 
 
Variety THC CBD Terpenic  
profile 
Provenance 
 
Bedrocan =22% <1% Sativa Netherlands 
Bedrobinol =12% <1% Sativa Netherlands 
Bediol =6.5% =8% Sativa Netherlands 
Bedica =14% <1% Indica Netherlands 
Bedrolite <1% =9% Sativa Netherlands 
FM2 5-8% 7.5-12% Sativa Italy  
FM1 13-20% <1% Sativa Italy 
Pedanios 
Aurora 
=22% <1% Sativa Canada  
Pedanios 
Aurora 
=8% =8% Indica Canada 
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The inflorescences are changed into 0.5-0.4 mm granules,and dispensed as capsule or pods (bedrolite and bediol 
are already granular). 
All can be extracted in oil using the SIFAP ethod:70 mg/ml-1gtt=2.5 mg-12 gtt 30 mg 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Possible mechanisms of cannabinoids action in different rheumatic diseases 
 
Pedanios 
Aurora  
<1% =9-12% Hybrid  Canada  
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                  Possible   Cannabinoids Action 
Rheumatoid arthritis 
 
Reduction of: 
• cytokine production by RA fibroblasts, 
release MMPs from fibroblast-like 
synovial cells, 
• interleukin 1 (IL-1) induced 
proteoglycan and collagen degradation,
• cartilage extracellular matrix (ECM) 
breakdown 
Osteoarthritis Possible pathway: 
• Exposure of OA chondrocytes to WIN 
55,212-2 mesylate reduced the activity 
of metalloproteinases and nitric oxide 
production 
• chondrocyte apoptosis (AEA decreases 
the viability of murine chondrocytes, 
and thus potentially contributes to 
cartilage destruction) 
Systemic lupus erythematosus Modulation of 2 AG levels, CBr2 expression 
Systemic sclerosis Downregulation of CBr1and upregulation of 
CBr-2 expression reduces leukocyte infiltration 
and dermal thickening,collagen accumulation 
in blood vessels, skin macrophage infiltration, 
and mast cell degranulation , prevents the 
development of skin and lung fibrosis and 
reduces anti-DNA topoisomerase antibody 
levels and fibroblast proliferation 
Fibromyalgia  Pain relief 
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Table 3. Adverse effects of the medical use of cannabis and cannabinoids  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AE OR Short/Long Term References 
Psychoses 1.4 to 3.4 S Marconi 2016 
[115] 
Dizziness 5.09 S/L Whiting 2015 
[116] 
Dry Mouth 3.5 S/L Whiting 2015 
Nausea 2.08 S/L Whiting 2015 
Fatigue 2.00 S Whiting 2015 
Somnolence 2.83 S Whiting 2015 
Vomiting 1.67 S Whiting 2015 
Diarrhoea 1.65 S Whiting 2015 
Euphoria 4.08 S Whiting 2015 
Bipolar 
Symptoms 
3.0 S Gibbs 2015 
[117] 
Depression 1.3 S/L Lev-Ran 2014 
[118] 
Anxiety 
Disorders 
1.3 to 1.68 S Kedzior 2014 
[119] 
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Table 4. Reported adverse events associated with cannabis, synthetic cannabinoids and 
cannabis mimetics 
 
System Disorders References 
Respiratory system  74 
 Dyspnea   
 Pneumonia   
 Pleural effusion   
 Lower respiratory tracts infection   
 Pulmonary embolism  
Gastrointestinal system  75 
 Vomiting*  
 Diarrhea   
 Gastroenteritis   
 Abdominal pain  
 Duodenal ulcer   
 Constipation   
 Nausea*  
 Dry mouth*  
Nervous system  76-79 
 Relapse of multiple sclerosis  
 Convulsion   
 Cerebrovascular disorders   
 Dizziness*  
adolescent Deficiencies in memory, attention, 
Inhibition and verbal fluency, 
decline in IQ score 
80 
 Drug addiction  
Psychiatric system  81 
 Agitation/anxiety/depression*  
 Self-harm/suicide ideation  
 Psycosis/schizophrenia  
 Paranoia/allucinations  
Renal and urinary system  82 
 Acute kidney injury  
 Haematurya/proteinuria  
Cardiovascular system  83 
 Tachycardia*  
 Congestive heart failure   
Immune system  84 
 Increase incidences of common 
infectious diseases and viral 
infections 
 
Pregnancy   85 
 Intra uterine growth retardation  
 Congenital birth defects  
Effects on sperm and testicular 
health 
 86 
 A significant decline in sperm 
count, concentration and motility. 
Increase in abnormal sperm 
morphology in who smoked 
cannabis 
 
 
*depending on the age of the user 
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Table 5. Possible interactions between cannabis and other pharmacological products 
DRUGS 
 
INTERACTION’S RESULTS 
Olanzapine  Delirium 
SSRIs Mania  
Cocaine  Tachycardia/Euphoria 
Ethanol  Increase THC 
Warfarin  Increase INR 
Sildenafil  Myocardial infarction 
Tricyclics  Delirium/Tachycardia 
Barbitures  CSN Depression 
 
 
Table 6. Contraindications to cannabis use 
Cannabis use is not recommended:  
Under 18 years age 
In patients with history of hypersensitivity to 
any cannabinoid or to smoke 
In patients with severe cardiopulmonary 
disease 
In patients with respiratory insufficiency 
(asthma or chronic obstructive pulmonary 
disease) 
In patients with personal history of psychiatric 
disorders (especially schizophrenia), or a 
familial history of schizophrenia. 
In patients with severe liver or renal disease. 
In women of childbearing 
age/pregnant/breastfeeding 
In patients receiving concomitant therapy with 
sedative-hypnotics or other psychoactive 
drugs  
 
  
